Short term efficacy of percutaneous balloon aortic valvuloplasty in the treatment of patients with calcified aortic stenosis

ZHOU Da-xin,PAN Wen-zhi,GUAN Li-hua,ZHANG Lei,ZHANG Xiao-chun,GE Jun-bo
DOI: https://doi.org/10.3969/j.issn.1004-8812.2015.10.002
2015-01-01
Abstract:Objective Percutaneous balloon aortic valvuloplasty( PBAV) is an optional treatment for the patients with calcified aortic stenosis( CAS). In this study,we observed the short-term effects of PBAV on CAS,and summarized our preliminary experiences. Methods Inoperable CAS patients were selected from October 2014 to March 2015. PBAV was performed using the 8-F PTA balloon catheter( Boston Scientific XXL). Diameter of the balloon used started from 12 mm,increased by 2 mm size step by step,and up to 18 mm. Results A total of 11 patients( 5 males) were included,with the average age of( 79. 2 ± 4. 7) years. All cases successfully underwent PBAV. There were 1case of left bundle branch block and 1 case of hypotension after operation. No other complications occurred. Immediately after the balloon dilation,the peak trans-valvular pressure gradient measured by the catheter was reduced from( 86. 6 ±22. 4) mm Hg to( 53. 2 ± 18. 7) mm( P 0. 01). Before discharge,echocardiography showed the peak trans-valvular pressure gradient was reduced from( 111. 0 ± 29. 2) mm Hg to( 85. 5 ± 26. 4) mm Hg( P 0. 01),the average trans-valvular pressure gradient was decreased from( 67. 1 ± 19. 6) mm Hg to( 48. 5 ±12. 2) mm Hg,and the aortic valve orifice area was increased from( 0. 58 ± 0. 10) cm2to( 0. 75 ± 0. 15)cm2( P 0. 01),while the left atrium,left ventricular diameter and left ventricular ejection fraction did not changed( P 0. 05). EQ5 D life quality score was improved( 54. 5 ± 15. 9 vs. 13. 3 ± 64. 6,P 0. 01).There were no changes in NYHA classification in 3 patients after operation and improvement by uptrend of 1class was recorded in the others( P 0. 01). One patient died of heart failure 2 months afterwards. Nine patients completed the 3 months follow-up. As compared with the time of discharge,there was no significant difference of trans-valvular pressure gradient,aortic valve orifice area and NYHA class( P 0. 05),and the quality of life( EQ5D) score was slightly improved( 10. 6 ± 9. 4 vs. 63. 5 ± 10. 6, P = 0. 04).Conclusions Our preliminary experience showed that PBAV using the 8-F balloon with the maximum diameter of 18 mm was safe,and could moderately improve the immediate and short-term hemodynamics and symptoms. Long-term effect needs to be further studied.
What problem does this paper attempt to address?